Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Brescia
Clinical trial register · Italy

Clinical Trials in Brescia, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 98 Roma 43 Naples 40 Rome 40 Rozzano 27
Narrow the registerReset
Recruitment status
Phase
Site location
Milan98 Roma43 Naples40 Rome40 Rozzano27
All 66 locations
Target enrolment
to

Trials with a site in Brescia

16 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Brescia, Lecco, Milan, Padova, Roma, Torino
2026-02-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Meldola, Aviano, Milan, Brescia, Catania, Padova, Roma, Torino
2026-01-19
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
360
Orbassano, Brescia, Milan, Naples, Roma
2025-07-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Naples, Misterbianco, Meldola (FC), Aviano, Rome, Brescia, Milan, Monza
2024-06-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Naples, Rome, Milan, Monza, Rozzano, Brescia, Genova, Novara
2024-06-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Bologna, Aviano, Rome, Milan, Rozzano, Candiolo, Bari, Brescia
2023-12-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Cona, Rome, Bergamo, Brescia, Milan, Monza, Turin, Palermo
2023-10-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
Bologna, Milan, Monza, Turin, Brescia
2021-12-13
Recruiting
Merck Sharp & Dohme LLC
Phase 2
355
Naples, Milan, Siena, Bologna, Brescia, Verona
2021-08-12
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Merck Sharp & Dohme LLC
Phase 2
490
Bari, Bologna, Brescia, Milan, Naples, Pavia, Reggio Emilia, Roma
2021-04-05
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 October 2026. https://priyalifescience.com/clinical-trials-italy/city/brescia

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies with a site in Brescia that also match the filters currently applied.

How many clinical trials are recruiting in Brescia?

9 of the 16 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Brescia), 16 studies
PhaseStudiesRecruitingShare
Phase 313681.3%
Phase 22212.5%
Phase 1/2116.3%

Most active sponsors

Lead sponsors with the most studies (Brescia)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC169
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.